Optimization of an in vitro drug screening assay for anti- Trypanosoma cruzi activity using epimastigotes
Chagas disease, caused by Trypanosoma cruzi, poses a significant global health burden. Current treatment relies solely on benznidazole and nifurtimox, both with limited efficacy and significant adverse effects. In vitro phenotype-based screening enables identification of alternative treatments. While epimastigote-bas...